Claris Lifesciences gets two product approvals from Russia

26 May 2011 Evaluate

Claris Lifesciences has received approval from the Ministry of Health (MoH), Russia, to market two more anti-infectives, namely Fluconazole IV 100 ml. and Levofloxacin IV 100 ml.

Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections, whereas Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. With the total pharmaceutical market size estimated at $11.2 billion and estimated to grow at 12-15 per cent CAGR, Russia is one of the largest and fastest growing pharmaceutical markets in the world. The generic market size in Russia is estimated to be at $3.5 billion.

With these two new approvals, Claris now has a basket of four major anti-infective products for Russia, including existing approved products, namely, Ciprofloxacin IV and Metronidazole IV. The total market size of these four parental products is estimated to be $53 million.

Peers
Company Name CMP
Redington 268.50
Adani Enterprises 2265.10
Amrapali Industries 15.02
Rashi Peripheral 325.05
PDS 339.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×